Back to today’s briefing

Story perspectives

Merck KGaA Acquires SpringWorks for $3.9 Billion Boost

5/1/2025

49 3

Summary

Story summary

Germany's Merck KGaA is set to make a significant move by acquiring U.S.-based SpringWorks Therapeutics for $3.9 billion, aiming to bolster its cancer treatment offerings, particularly for rare tumors. This strategic acquisition, anticipated to finalize in late 2025, will enhance Merck's foothold in the U.S. and drive growth in specialized healthcare, leveraging SpringWorks' FDA-approved therapies for desmoid tumors and neurofibromatosis type 1.

1 of 1

Story summary

Germany's Merck KGaA is set to make a significant move by acquiring U.S.-based SpringWorks Therapeutics for $3.9 billion, aiming to bolster its cancer treatment offerings, particularly for rare tumors. This strategic acquisition, anticipated to finalize in late 2025, will enhance Merck's foothold in the U.S. and drive growth in specialized healthcare, leveraging SpringWorks' FDA-approved therapies for desmoid tumors and neurofibromatosis type 1.